Severe chronic spontaneous urticaria

The PBS subsidises omalizumab for patients with severe chronic spontaneous urticaria.

Omalizumab can be subsidised through the PBS under section 100 of the National Health Act 1953 for patients with severe chronic spontaneous urticaria.

Section 100 arrangements

This item is only available to a patient who is attending:

  • an approved private hospital
  • a public participating hospital, or
  • a public hospital

and is a

  • day admitted patient
  • non-admitted patient, or
  • patient on discharge

These items are not available as a PBS benefit for in-patients of a hospital. The hospital provider name and number must be included on the application form.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing omalizumab.

Applications

Initial treatment

Make all initial applications for authority approval to prescribe PBS subsidised omalizumab for the treatment of severe chronic spontaneous urticaria in writing and:

All applications must include a completed:

Initial grandfather treatment

For patients who received non PBS subsidised omalizumab treatment for severe chronic spontaneous urticaria before 1 September 2017, make all initial grandfather applications in writing and:

All applications must include a completed:

A patient may qualify for PBS subsidised omalizumab under the grandfather restriction only one time.

Continuing treatment

Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

Page last updated: 1 October 2017